Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 345, Issue 4, pp 410–416

Presynaptic α2-adrenoceptors mediating inhibition of noradrenalh and 5-hydroxytryptamine release in rat cerebral cortex: further characterization as different α2-adrenoceptor subtynes

  • Guido Maura
  • Giambattista Bonanno
  • Maurizio Raiteri
Original Articles


In a previous investigation it was suggested that the α2-adrenoceptors regulating 3H-noradrenaline (3H-NA) release and the α2-heteroreceptors regulating the release of 3H-5-hydroxytryptamine (3H-5-HT) from rat cerebrocortex synaptosomes represent different subtypes of the α2-adrenoceptor in that (−)-mianserin potently blocked the receptors sited on 5-HT terminals but was ineffective at the autoreceptors (Raiteri et al. 1983).

In this work a number of α2-adrenoceptor antagonists were tested against NA as an inhibitor of the K+ (15 mmol/l)-evoked release of 3H-NA or 3H-5-HT (in presence of 1 μmol/l desipramine or citalopram, respectively) from superfused rat neocortex synaptosomes. The order of apparent affinity of the antagonists was: idazoxan ≥ ORG 20769 (2-amino-4-(1-methyl-1,2,3, 6-tetrahydropyridin-4-yl)-thiazole-5-carbonitrile (Z)-2-butenedioate (1:1) salt) ≥ ORG 20350 (5-chloro-4-(1-butyl-1,2,5,6-tetrahydropyridin-3-yl)-thiazole-2-amine (Z)-2-butenedioate (1:1) salt) ≥ ORG 20091 (5-chloro-4-(1-methyl -1,2,5,6-tetrahydropyridin -3- yl)-thiazole-2-amine (Z)-2-butenedioate (2:1) salt) at the α2-autoreceptor and idazoxan ≥ ORG 20769 > ORG 20091 » ORG 20350 at the α2-heteroreceptor. Prazosin (1 gmol/l) or AR-C 239 (1 gmol/l) (2-[2-[4-(o-methoxyphenyl)piperazine-l-yl]ethyl]-4,4-dimethyl-1,3(2H,4H)isoquinolinedione) were ineffective in both systems.

Idazoxan and ORG 20769 had a comparable apparent affinity at the α2-autoreceptor (pKB values: 8.45 and 8.42, respectively) and at the heteroreceptor (pKB values: 8.16 and 8.15, respectively). In contrast, ORG 20350 was about 14-fold less. potent than the two previous compounds at the autoreceptor (pKB = 7.30) whereas it was ineffective at the heteroreceptor when tested up to 3 μmol/l (pKB < 5.5). Experiments with electrically-stimulated (2 Hz; 2 ms; 24 mA) rat cerebral cortex slices confirmed the data with synaptosomes. ORG 20350 shifted to the right in a parallel manner the concentration-response curve of clonidine at the α2-autoreceptors (pA2 = 7.25). The sulphydryl alkylating agent N-ethyl-maleimide (NEM; 3 μmol/l) which has been proposed to inactivate pertussis toxin sensitive G proteins, abolished the inhibition of both 3H-NA and 3H-5-HT release caused by the α2-adrenoceptor agonist clonidine (0.3 μmol/l) in hippocampus synaptosomes. The effect of exposure to NEM was not modified during “protection” experiments with idazoxan.

The results lend further support to the proposed existence of functional α2-adrenoceptor subtypes. It should be noted that the two pharmacologically distinct receptors here characterized are present in the same brain area and within the same animal species. They are sited on the axon terminals of different neurons. Their function appears that of inhibiting NA or 5-HT release, respectively. Both α2-auto- and heteroreceptors are likely to be coupled to G proteins. According to the current nomenclature, the receptors do not seem to belong to the α2B subtype. However only one of them might be classified as α2A.

Key words

α2-Adrenoceptor subtypes 3H-NA release 3H-5-HT release Rat cerebral cortex G Proteins Clonidine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alabaster VA, Peters CJ (1984) Pre- and postjunctional alpha2 adrenoceptors can be differentially antagonised. Br J Pharmacol 81:163PGoogle Scholar
  2. Alabaster VA, Keir RF, Peters CJ (1986) Comparison of potency of α2-adrenoceptor antagonists in vitro: evidence for heterogeneity of α2-adrenoceptors. Br J Pharmacol 88:607–614Google Scholar
  3. Allgaier C, Feuerstein TJ, Hertting G (1986) N-ethylmaleimide (NEM) diminishes alpha2-adrenoceptor mediated effects on noradrenaline release. Naunyn-Schmiedeberg's Arch Pharmacol 333:104–109Google Scholar
  4. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48–58Google Scholar
  5. Bonanno G, Raiteri M (1987) Interaction between 5-HT uptake inhibition and activation of 5-HT autoreceptors by exogenous agonists in rat cerebral cortex slices and synaptosomes. Naunyn-Schmiedeberg's Arch Pharmacol 335:219–225Google Scholar
  6. Boyajian CL, Leslie FM (1987) Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain. J Pharmacol Exp Ther 241:1092–1098Google Scholar
  7. Bylund DB (1981) Comparison of [3H]clonidine and [3H]yohimbine binding: Possible subtypes of alpha-2 adrenergic receptors. Pharmacologist 23:215Google Scholar
  8. Bylund DB (1985) Heterogeneity of alpha-2 adrenergic receptors. Pharmacol Biochem Behav 22:835–843Google Scholar
  9. Bylund DB (1988) Subtypes of α2-adrenoceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci 9:356–361Google Scholar
  10. Bylund DB, Ray-Prenger C (1989) Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype. J Pharmacol Exp Ther 251:640–644Google Scholar
  11. Cheng YC, Prusoff NH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108CrossRefPubMedGoogle Scholar
  12. Cheung Y-D, Barnett DB, Nahorski SR (1982) [3H]rauwolscine and [3H]yohimbine binding to rat cerebral and human platelet membranes: possible heterogeneity of α2-adrenoceptors. Eur J Pharmacol 84:79–85Google Scholar
  13. Connaughton S, Docherty JR (1990) Functional evidence for heterogeneity of peripheral prejunctional α2-adrenoceptors. Br J Pharmacol 101:285–290Google Scholar
  14. Dickinson KEJ, McKernan RM, Miles CMM, Leys KS, Sever PS (1986) Heterogeneity of mammalian α2-adrenoceptors delineated by [3H]yohimbine binding. Eur J Pharmacol 120:285–293Google Scholar
  15. Feller DJ, Bylund DB (1984) Comparison of alpha-2-adrenergic receptors and their regulation in rodent and porcine species. J Pharmacol Exp Ther 228:275–282Google Scholar
  16. Frankhuyzen AL, Mulder AH (1982a) A cumulative dose-response technique for the characterization of presynaptic receptors modulating [3H]noradrenaline release from rat brain slices. Eur J Pharmacol 78:91–97Google Scholar
  17. Frankhuyzen AL, Mulder AH (1982b) Pharmacological characterization of presynaptic α-adrenoceptors modulating [3H]noradrenaline and [3H]5-hydroxytryptamine release from slices of the hippocampus of the rat. Eur J Pharmacol 81:97–106Google Scholar
  18. Frankhuyzen AL, Wardeh G, Hogenboom F, Mulder AH (1988) α2-Adrenoceptor mediated inhibition of the release of radiolabelled 5-hydroxytryptamine and noradrenaline from slices of the dorsal region of the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 337:255–260Google Scholar
  19. Gilman AG (1987) G proteins: transducers of receptor-generated signals. Ann Rev Biochem 56:615–649Google Scholar
  20. Gobbi M, Frittoli E, Mennini T (1990) The modulation of [3H]noradrenaline and [3H]serotonin release from rat brain synaptosomes is not mediated by the α2B-adrenoceptor subtype. Naunyn-Schmiedeberg's Arch Pharmacol 342:382–386Google Scholar
  21. Göthert M, Huth H, Schlicker E (1981) Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn-Schmiedeberg's Arch Pharmacol 317:199–203Google Scholar
  22. Gray EG, Whittaker VP (1962) The isolation of nerve endings from brain: An electron microscopic study of cell fragments derived by homogenization and centrifugation. J Anat 96:79–87Google Scholar
  23. Harrison JK, D'Angelo DD, Zeng D, Lynch KR (1991) Pharmacological characterization of rat α2-adrenergic receptors. Mol Pharmacol 40:407–412Google Scholar
  24. Jakobs KH, Lasch P, Minuth M, Aktories K, Schultz G (1982) Uncoupling of α-adrenoceptor-mediated inhibition of human platelet adenylate cyclase by N-ethylmaleimide. J Biol Chem 257:2829–2833Google Scholar
  25. Kapocsi J, Somogyi GT, Ludvig N, Serfozo P, Harsing LG Jr, Woods RJ, Vizi ES (1987) Neurochemical evidence for two types of presynaptic alpha2-adrenoceptors. Neurochem Res 12:141–147Google Scholar
  26. Kobilka BK, Matsui H, Kobilka TS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ, Regan JW (1987) Cloning, sequencing, and expression of the gene coding for the human platelet α2-adrenergic receptor. Science 238:650–656PubMedGoogle Scholar
  27. Latifpour J, Jones SB, Bylund DB (1982) Characterization of [3H]yohimbine binding to putative alpha-2 adrenergic receptors in neonatal rat lung. J Pharmacol Exp Ther 223:606–611Google Scholar
  28. Limberger N, Späth L, Starke K (1991) Subclassification of the presynaptic α2-autoreceptors in rabbit brain cortex. Br J Pharmacol 103:1251–1255Google Scholar
  29. Maura G, Gemignani A, Raiteri M (1985) α2-adrenoceptors in rat hypothalamus and cerebral cortex: functional evidence for pharmacologically distinct subpopulations. Eur J Pharmacol 116:335–339Google Scholar
  30. Nahorski SR, Barnett DB, Cheung Y-D (1985) α-Adrenoceptor-effector coupling: Affinity states or heterogeneity of the α-adrenoceptor? Clin Sci 68:29s-42sGoogle Scholar
  31. Raiteri M, Angelini F, Levi G (1974) A simple apparatus for studying the release of neurotransmitters from synaptosomes. Eur J Pharmacol 25:411–414Google Scholar
  32. Raiteri M, Maura G, Versace P (1983) Functional evidence for two stereochemically different alpha-2 adrenoceptors regulating central norepinephrine and serotonin release. J Pharmacol Exp Ther 224:679–684Google Scholar
  33. Raiteri M, Bonanno G, Marchi M, Maura G (1984) Is there a functional linkage between neurotransmitter uptake mechanisms and presynaptic receptors? J Pharmacol Exp Ther 231:671–677Google Scholar
  34. Regan JW, Kobilka TS, Yang-Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK (1988) Cloning and expression of a human kidney cDNA for an α2-adrenergic receptor subtype. Proc Natl Acad Sci USA 85:6301–6305PubMedGoogle Scholar
  35. Ruffolo RR Jr, Sulpizio AC, Nichols AJ, DeMarinis RM, Hieble JP (1987) Pharmacologic differentiation between pre- and postjunctional α2-adrenoceptors by SK & F 104078. Naunyn-Schmiedeberg's Arch Pharmacol 336:415–418Google Scholar
  36. Summers RJ, Barnett DB, Nahorski SR (1983) The characteristics of adrenoceptors in homogenates of human cerebral cortex labelled by [3H]rauwolscine. Life Sci 33:1105–1112Google Scholar
  37. Tallarida RJ, Jakobs LS (1979) The dose-response relation in pharmacology. Springer, Heidelberg Berlin New YorkGoogle Scholar
  38. Wurster S, Nakov R, Allgaier C, Hertting G (1990) Involvement of N-ethylmaleimide-sensitive G proteins in the modulation of evoked [3H]noradrenaline release from rabbit hippocampus synaptosomes. Neurochem Int 17:149–155Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Guido Maura
    • 1
  • Giambattista Bonanno
    • 1
  • Maurizio Raiteri
    • 1
  1. 1.Istituto di Farmacologia e FarmacognosiaUniversità degli Studi di GenovaGenovaItaly

Personalised recommendations